Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,064.01
(
-0.63%
)
US TECH 100
25,899.60
(
0.11%
)
Dow Jones
49,149.38
(
-0.60%
)
Brent Oil
94.06
(
-1.01%
)
Bitcoin
77,605.64
(
1.67%
)
News Focus
News Focus
Post# of 257433
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122881
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 239515

Thursday, 05/16/2024 1:31:51 PM

Thursday, May 16, 2024 1:31:51 PM

Post# of 257433
FWBI—>ENTO (Entero Therapeutics) effective 5/17/24:

https://www.globenewswire.com/news-release/2024/05/16/2883267/0/en/First-Wave-BioPharma-Changes-Name-to-Entero-Therapeutics.html

The name change stems from a reverse-merger that closed in Mar 2024, whereby FWBI merged with (then private) ImmunogenX, whose lead program is for celiac disease (https://finance.yahoo.com/news/first-wave-biopharma-announces-completion-100000036.html ).

FWBI was itself the product of a 2021 reverse-merger (#msg-165885811).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today